Form 4: Apogee Therapeutics Insider Reports Stock Transaction
Insider Transaction (Form 4)
Fairmount Funds Management LLC and 3 others reported changes in beneficial ownership of Apogee Therapeutics, Inc. common stock on September 3, 2026.
Summary
- Disposition to the issuer: disposed of 340,855 Common Stock on September 3, 2026 (Indirect).
- Disposition to the issuer: disposed of 51,166 Common Stock on September 3, 2026 (Indirect).
- Disposition to the issuer: disposed of 51,166 Common Stock on September 3, 2026 (Indirect).
- Disposition to the issuer: disposed of 6,743,321 Non-Voting Common Stock on September 3, 2026 (Indirect).
- Disposition to the issuer: disposed of 47,758 Stock Option (Right to Buy) on September 3, 2026 (Indirect).
- Disposition to the issuer: disposed of 10,370 Stock Option (Right to Buy) on September 3, 2026 (Indirect).
- Disposition to the issuer: disposed of 14,461 Stock Option (Right to Buy) on September 3, 2026 (Indirect).
- Disposition to the issuer: disposed of 7,657 Stock Option (Right to Buy) on September 3, 2026 (Indirect).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Fairmount Funds Management LLC — Director
Fairmount Healthcare Fund II L.P. — Director
Tomas Kiselak — Director
Peter Evan Harwin — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-03 | Disposition to the issuer | Common Stock | 340,855 | — | — | 0 |
| 2026-09-03 | Disposition to the issuer | Common Stock | 51,166 | — | — | 0 |
| 2026-09-03 | Disposition to the issuer | Common Stock | 51,166 | — | — | 0 |
| 2026-09-03 | Disposition to the issuer | Non-Voting Common Stock | 6,743,321 | — | — | 0 |
| 2026-09-03 | Disposition to the issuer | Stock Option (Right to Buy) | 47,758 | — | — | 0 |
| 2026-09-03 | Disposition to the issuer | Stock Option (Right to Buy) | 10,370 | — | — | 0 |
| 2026-09-03 | Disposition to the issuer | Stock Option (Right to Buy) | 14,461 | — | — | 0 |
| 2026-09-03 | Disposition to the issuer | Stock Option (Right to Buy) | 7,657 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-03 | Disposition to the issuer (340,855 shares) |
| 2026-09-03 | Disposition to the issuer (51,166 shares) |
| 2026-09-03 | Disposition to the issuer (51,166 shares) |
| 2026-09-03 | Disposition to the issuer (6,743,321 shares) |
| 2026-09-03 | Disposition to the issuer (47,758 shares) |
| 2026-09-03 | Disposition to the issuer (10,370 shares) |
| 2026-09-03 | Disposition to the issuer (14,461 shares) |
| 2026-09-03 | Disposition to the issuer (7,657 shares) |
Keywords
insider transaction, Form 4, APGE, Apogee Therapeutics, Inc., neutral, Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Tomas Kiselak, Peter Evan Harwin
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.